Paliperidone

證據等級: L5

預測適應症: 10 個

Paliperidone: From Schizophrenia to Treatment-Refractory Schizophrenia

One-Sentence Summary

Paliperidone is an antipsychotic (the active metabolite of risperidone, D2/5-HT2A receptor antagonist) already used for schizophrenia-spectrum disorders. The TxGNN model returned nine higher-scoring predictions (retinal dystrophy, X-linked/syndromic myopia, hydranencephaly, a glycosylation disorder, CMT type 1G, glycine encephalopathy) that the evidence pack itself flags as mechanistically implausible with zero supporting trials or literature — these are treated as model noise, not candidates. The only prediction with real support is an extension into treatment-refractory schizophrenia, backed by 4 clinical trials and 2 publications.

Quick Overview

Item	Content
Original Indication	Not documented in the Norway licensing data (0 authorizations); mechanistically established as schizophrenia/schizoaffective disorder per the drug's known antipsychotic class
Predicted New Indication	Treatment-Refractory Schizophrenia (selected from rank 10 — see note below on why rank 1 was not used)
TxGNN Prediction Score	99.80% (score 0.99796, rank 2663)
Evidence Level	L2
Norway Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Note on ranking: TxGNN's top 9 predictions by score (rank 1 = retinal dystrophy at 99.92%, down through glycine encephalopathy) have no clinical trials, no literature, and no mechanistic rationale — the evidence pack's own annotations explicitly state there is "no identifiable pharmacological mechanism link" for each. These are disregarded as spurious graph-noise signals. The lowest-scoring prediction in this set, treatment-refractory schizophrenia (rank 10, still >99.7% score), is the only one with real trial and literature backing and a coherent mechanism, so it is used as the featured candidate in this report.

Why is This Prediction Reasonable?

Drug-level mechanism of action data is formally flagged as a gap (DG002, High severity) — no structured MOA record was retrievable from DrugBank at this cutoff. However, the evidence pack's own repurposing rationale documents that paliperidone is the active metabolite of risperidone and acts as a D2/5-HT2A receptor antagonist, which is the core pharmacological mechanism underlying antipsychotic therapy.

This is not a cross-disease repurposing case in the classic sense — paliperidone's established therapeutic class already targets schizophrenia. The "new indication" here is better understood as an extension of use into a treatment-resistant subpopulation of the same disease, supported by real-world naturalistic and comparative-effectiveness trial designs (e.g., paliperidone palmitate case series, aripiprazole-vs-paliperidone multi-omics RCT). This is mechanistically coherent and lower-risk than the other nine model predictions, which involve unrelated congenital, ophthalmologic, neurodevelopmental, and metabolic disorders with no plausible link to central dopamine/serotonin receptor blockade.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01860781	Phase 4	Completed	30	Prospective naturalistic case series evaluating paliperidone palmitate effectiveness across three schizophrenia patient subgroups
NCT07047651	Phase 4	Recruiting	40	Combines pharmacotherapy with recovery-oriented programs (RECOVERYTRSGR/RECOVERYTRSBDGR) for treatment-resistant schizophrenia and bipolar disorder
NCT05741502	Phase 4	Terminated	5	Compared clozapine vs. non-clozapine antipsychotics on inflammatory markers in treatment-refractory schizophrenia; low relevance, terminated early with minimal enrollment
NCT06060886	Phase 4	Unknown status	244	Open-label multicenter RCT (SchizOMICS) comparing aripiprazole vs. paliperidone/risperidone using multi-omics data in first-episode psychosis

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31648341	2019	Review	Actas Españolas de Psiquiatría	Reviews antipsychotic pharmacotherapy evidence for schizoaffective disorder, noting the lack of disorder-specific treatment guidelines
23364281	2013	Review	Current Opinion in Psychiatry	Evidence-informed pharmacological approach for early-onset schizophrenia spectrum disorders, including dosing and adverse-effect monitoring

Norway Market Information

No marketing authorizations were found for paliperidone in the Norway regulatory dataset (taiwan_regulatory.total_licenses = 0; market status: 未上市 / Not marketed).

Safety Considerations

Please refer to the package insert for safety information. A blocking data gap (DG001) exists: TFDA-equivalent label warnings and contraindications for paliperidone could not be retrieved at this cutoff, which prevents this candidate from entering the S1 safety pre-assessment stage. No drug-drug interaction records were found in the current query (ddi.query_status: not_found).

Conclusion and Next Steps

Decision: Hold

Rationale: While the treatment-refractory schizophrenia indication has coherent mechanistic rationale and moderate clinical evidence (L2, 4 trials, 2 reviews) that would otherwise support a "Proceed with Guardrails" call, the drug-level safety data gap (DG001, Blocking) means this candidate cannot yet enter the S1 safety pre-assessment, and the drug is not currently marketed in Norway (0 authorizations). The nine other TxGNN-flagged indications (retinal dystrophy, myopia subtypes, hydranencephaly, glycosylation disorder, CMT type 1G, glycine encephalopathy) should be excluded from further evaluation — they have no clinical, literature, or mechanistic support and appear to be knowledge-graph artifacts.

To proceed, the following is needed:

Retrieve TFDA-equivalent label warnings/contraindications (DG001) to unblock S1 safety review
Retrieve structured MOA data from DrugBank (DG002) to formally support the mechanistic rationale
Confirm Norway marketing/import pathway status, since the drug currently has zero local authorizations
If DG001/DG002 are resolved favorably, re-score treatment-refractory schizophrenia for "Proceed with Guardrails" and define specific monitoring guardrails (e.g., metabolic/EPS monitoring per antipsychotic class norms)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.